264 related articles for article (PubMed ID: 32313185)
21. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.
Williamson SR; Zhang S; Yao JL; Huang J; Lopez-Beltran A; Shen S; Osunkoya AO; MacLennan GT; Montironi R; Cheng L
Mod Pathol; 2011 Aug; 24(8):1120-7. PubMed ID: 21499238
[TBL] [Abstract][Full Text] [Related]
22. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall.
Mirsadraei L; Hodkoff A; Jones K; Shabaik A; Kader AK; Saenz CC; Montironi R; Tacha DE; Fadare O; Hansel DE
Arch Pathol Lab Med; 2018 Feb; 142(2):168-177. PubMed ID: 28795841
[TBL] [Abstract][Full Text] [Related]
23. [Case of bladder cancer following adjuvant external beam radiation for prostate cancer].
Nishikawa K; Soga N; Kato M; Masui S; Hasegawa Y; Yamada Y; Kise H; Arima K; Sugimura Y
Hinyokika Kiyo; 2009 Jan; 55(1):39-41. PubMed ID: 19227212
[TBL] [Abstract][Full Text] [Related]
24. [Metastatic lymph node collision of a prostatic adenocarcinoma and an urothelial carcinoma and review of the literature].
Junca A; Frouin E; Irani J; Fromont G; Levillain P
Ann Pathol; 2015 Dec; 35(6):496-501. PubMed ID: 26597142
[TBL] [Abstract][Full Text] [Related]
25. Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate.
Gardner JM; Khurana H; Leach FS; Ayala AG; Zhai J; Ro JY
Arch Pathol Lab Med; 2010 Sep; 134(9):1271-5. PubMed ID: 20807045
[TBL] [Abstract][Full Text] [Related]
26. Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Ch'ng ES
Sci Rep; 2021 Mar; 11(1):6765. PubMed ID: 33762601
[TBL] [Abstract][Full Text] [Related]
27. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
Fatima N; Osunkoya AO
Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
[TBL] [Abstract][Full Text] [Related]
28. High-grade Adenocarcinoma of the Prostate Mimicking Urothelial Carcinoma is Negative for TERT Mutations.
Alaghehbandan R; Vanecek T; Trpkov K; Comperat E; Kristiansen G; Svajdler M; Cempirkova D; Pavlovsky M; Pivovarcikova K; Stehlikova A; Hora M; Michal M; Hes O
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):523-528. PubMed ID: 31393284
[TBL] [Abstract][Full Text] [Related]
29. Urothelial carcinoma of the urinary bladder with a component of acinar/tubular type differentiation simulating prostatic adenocarcinoma.
Huang Q; Chu PG; Lau SK; Weiss LM
Hum Pathol; 2004 Jun; 35(6):769-73. PubMed ID: 15188146
[TBL] [Abstract][Full Text] [Related]
30. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical differential diagnosis between urothelial carcinoma and prostate adenocarcinoma among Egyptian patients.
Sakr SA; Abdel-Wahed MM; El-Sahra DG
Biomed Pharmacother; 2014 Jul; 68(6):685-92. PubMed ID: 25194443
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic utility of GATA3 immunohistochemical expression in urothelial carcinoma.
Agarwal H; Babu S; Rana C; Kumar M; Singhai A; Shankhwar SN; Singh V; Sinha RJ
Indian J Pathol Microbiol; 2019; 62(2):244-250. PubMed ID: 30971548
[TBL] [Abstract][Full Text] [Related]
33. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
34. Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems.
Oliva E; Amin MB; Jimenez R; Young RH
Am J Surg Pathol; 2002 Feb; 26(2):190-7. PubMed ID: 11812940
[TBL] [Abstract][Full Text] [Related]
35. Prostatic Ductal Adenocarcinoma with Papillary Features in a Bladder Washing: A Possible Pitfall in Urinary Cytology - Report of One Case.
Barizzi J; Freguia S; Sarro R; Venzi G; Fulciniti F
Acta Cytol; 2020; 64(6):607-611. PubMed ID: 32498072
[TBL] [Abstract][Full Text] [Related]
36. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
Bontoux C; Rialland T; Cussenot O; Compérat E
Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
[TBL] [Abstract][Full Text] [Related]
37. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
38. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
[TBL] [Abstract][Full Text] [Related]
39. Synchronous Penile Squamous Cell Carcinoma, Bladder Urothelial Carcinoma and Prostate Adenocarcinoma Diagnosed in One Procedure.
Deng F; Kong MX; Lai J
Anticancer Res; 2022 Jul; 42(7):3601-3605. PubMed ID: 35790255
[TBL] [Abstract][Full Text] [Related]
40. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
